Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials
Authors' conclusion
No response ACR Pedi 50 or more by month 1 after treatment was associated with a 0.60 probability of responding by month 4, but not responding by month 3 was associated with a 0.31 probability of response by month 4. Baseline disease duration, rheumatoid factor, and active joint counts predicted early treatment response (ACR and cJADAS10 states).
Study context
- Population
- Children with JIA starting biologic disease-modifying antirheumatic drugs (bDMARDs) in the open-label run-in period (first 16 weeks) of 4 bDMARD trials70% on MTX, 41% prednisone
- Participants
- 532 children
- Primary endpoint
- ACR Pedi 50 or greater (clinically significant response)
- Follow-up
- Month 4
Methodological detailsopen-label run-in period, inhomogeneous Markov multistate model
- Open-label run-in period
- Inhomogeneous Markov multistate model
Primary result
As reported in the abstract
Probability of American College of Rheumatology (ACR) Pedi 50 or greater by month 4
0.698
Probability by month 4 if ACR Pedi 50 or more not achieved by month 1
0.60
Probability by month 4 if ACR Pedi 50 or more not achieved by month 3
0.31
Secondary outcomes
Predictors of ACR and cJADAS state transitions
- Age at diagnosis, disease duration, baseline RF and active joint counts predicted ACR and cJADAS state transitions, adjusted for concomitant treatment
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →